Two studies found that patients prescribed GLP-1 receptor agonists for obesity were often discontinuing the medication before seeing meaningful weight loss results. Factors influencing discontinuation included age, access to healthcare, provider specialty, co-pays, comorbidities, and gender and ethnicity. Patients with obesity were more likely to stop taking the medication compared to those with diabetes. Discontinuation could have implications for policy and medication coverage if weight reduction is not sustained after stopping the medication. More research is needed to understand the reasons behind discontinuation and potential strategies to improve adherence to GLP-1 therapies for obesity.
Source link
GLP-1 Discontinuation Less Common With Endocrinologists
